Shares of Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of C$1.45 and traded as high as C$1.50. Oncolytics Biotech shares last traded at C$1.48, with a volume of 107,682 shares changing hands.
Analysts Set New Price Targets
Separately, Raymond James raised their price objective on shares of Oncolytics Biotech from C$3.00 to C$3.50 in a research report on Friday, September 20th.
Read Our Latest Research Report on ONC
Oncolytics Biotech Trading Down 1.3 %
The firm has a market cap of C$113.75 million, a PE ratio of -3.89 and a beta of 1.35. The company's fifty day moving average price is C$1.48 and its two-hundred day moving average price is C$1.45. The company has a quick ratio of 8.86, a current ratio of 4.99 and a debt-to-equity ratio of 6.09.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
